Oncology

Oncology is the most advanced area in genomics right now. The field is setting the standard for other indications to follow and improve upon.

Bristol-Myers Squibb to Buy Celgene for $74bn

Bristol-Myers Squibb (BMS) has announced intentions to buy Celgene for $74bn. This transaction, the fourth largest such deal in pharma history, will give BMS access to several cancer franchises, including experimental cell therapies which attack tumours.

Reprogrammed Skin Cells Shrink Mouse Tumours

Personalised tumour-detecting cells from adult skin cells have been used to shrink brain tumours in mice by up to 5%, scientists have revealed. While the strategy has not yet been fully tested in people, it could in the future give doctors the ability to develop a custom treatment for certain cancer types.

CRUK and AstraZeneca to Launch New Genomics Centre in UK

AstraZeneca and Cancer Research UK (CRUK) have announced that they will work together to open a new research centre in the UK, applying CRISPR and other functional genomics technologies to develop new cancer drugs. Specifically, the centre will study how genes and proteins interact with each other in cancer cells, and create disease models using genome-altering technologies based on this.

Scientists Create Ten-Minute Universal Test for Cancer

A universal test which can detect traces of any cancer in a patient’s bloodstream in ten minutes has been developed by scientists from the University of Queensland. As it stands the test has a sensitivity of 90%, so is able to detect 90 in 100 cases of cancer.

Defective DNA Repair Leads to Genome “Chaos”

Scientists have found a cause for the frequent and damaging events in cancer cells’ genetic material where sections of individual chromosomes were broken at a number of points and reassembled wrongly, so entire sections were missing and others were duplicated or incorporated in a wrong orientation.